Peptech earns TNF patent protection in US
10 July, 2002 by Tanya HollisSydney-based biotech Peptech has gained United States patent protection for its tumour necrotising factor (TNF) antibodies, priming the company for its next growth phase.
EQiTX sets itself up for biotechnology
09 July, 2002 by Tanya HollisA Western Australian oil and metal exploration company has gathered some of the top names in Australian science as it moves towards rebirth as a biotech.
BioProspect's Japanese Qcide deal
09 July, 2002 by Tanya HollisNatural insecticide developer BioProspect has reached a second deal over rights to test its new product.
Cone snail venom could treat chronic pain
08 July, 2002 by Melissa TrudingerA novel compound from the venom of a cone shell marine snail found on the Great Barrier Reef may have a use as a drug to treat chronic pain, according to scientists from the University of Melbourne and the National Ageing Research Institute.
BresaGen halts study on leukaemia drug
08 July, 2002 by Tanya HollisA leukaemia drug developed by Adelaide biotech BresaGen will go back to the drawing board after it was found not to be as effective as previously thought against one form of the disease.
Cardia subsidiary Bioglobal buys blowfly IP
08 July, 2002 by Melissa TrudingerCardia Technologies subsidiary Bioglobal has bought intellectual property from Queensland's Department of Primary Industries relating to blowfly attract and kill technology.
Give it a myth: the big assumptions about GM
05 July, 2002 by Melissa TrudingerSeveral myths, misconceptions and assumptions about genetically modified organisms and food have made their way into the public arena. What doesn't help the average punter to get a grip on the science is that there are huge swathes of information available, from scientists, policy-makers, lobbyists and industry. And for every opinion exists its opposite.
New research eases strain on artificial muscle
05 July, 2002 by Tanya HollisAustralian researchers have created salt-based liquids that improve the performance of artificial muscle by thousands of times.
Shareholders back MicroMedical name change
05 July, 2002 by Tanya HollisA proposed name change for artificial heart developer MicroMedical Industries has gained the backing of nearly all its shareholders.
Ambri re-brands in lead-up to diagnostic launch
05 July, 2002 by Melissa TrudingerAmbri has launched a corporate re-branding campaign as it prepares to launch testing of its SensiDx point-of-care diagnostic system in Australian hospitals.
Biotechs fear OGTR cost recovery could quash R&D
05 July, 2002 by Melissa TrudingerPlant biotechnologists in Australia are concerned that implementation of a full cost recovery scheme for the Office of the Gene Technology Regulator will make the cost of developing new GM crop varieties too expensive for small biotechnology companies and public research institutions to consider.
Chemeq's drug approved for sale in South Africa
04 July, 2002 by Melissa TrudingerChemeq has announced that it has received its first regulatory approval for sale of its veterinary drug CHEMEQ polymeric antimicrobial in South Africa.
Views on GM polarised: WA survey
04 July, 2002 by Pete YoungA Western Australian government survey of public and industry views has revealed strongly-polarised views about the costs and benefits of introducing genetically modified crops, says Agriculture Minister Kim Chance.
Federal funding recieved for foot and mouth monitoring
03 July, 2002 by Melissa TrudingerCSIRO's Australian Animal Health Laboratory has received $1 million from the Federal government to improve systems for prevention of foot and mouth disease outbreaks in Australia.
CSIRO and GRDC team up to study grain crop problems
03 July, 2002 by Melissa TrudingerCSIRO Entomology and the Grains Research and Development Corporation have signed a $20 million agreement for a research alliance focusing on the pests and diseases affecting Australia's grain industries.
